GSK nix­es Spring­Works li­cens­ing deal fo­cused on Blenrep-Og­siveo for blood can­cer

GSK is walk­ing away from an ex­pand­ed part­ner­ship deal with Spring­Works Ther­a­peu­tics, wind­ing down fur­ther re­search ac­tiv­i­ties that would com­bine Blenrep and Og­siveo.

The UK …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.